The cash runway to Q3 2026 creates an imminent financing overhang. Traders should watch for partnership announcements or royalty deals for lacutamab, as failure to secure non-dilutive financing before Q3 2026 would likely force dilutive equity raise or restructuring. The PACIFIC-9 readout in H2 2026 is a binary catalyst but is secondary to the near-term liquidity risk.
Price Chart
Executive Summary
Innate Pharma reported Q1 2026 revenue of €2.6M (up from €1.2M YoY) but disclosed a cash position of only €25.4M, providing runway only until end of Q3 2026. The confirmatory Phase 3 TELLOMAK-3 trial for lacutamab remains contingent on securing non-dilutive financing, while the PACIFIC-9 data readout (monalizumab) is expected in H2 2026. The company's ability to continue as a going concern without immediate financing is the dominant risk, overriding positive pipeline updates.
Key Facts
- Cash position of €25.4M as of March 31, 2026, with runway only until end of Q3 2026
- Q1 2026 revenue of €2.6M vs €1.2M in Q1 2025
- Financial liabilities of €20.3M as of March 31, 2026
- TELLOMAK-3 Phase 3 trial initiation in H2 2026 is contingent on non-dilutive financing (pharma partnering or royalty structures)
- PACIFIC-9 Phase 3 data readout for monalizumab expected H2 2026
- IPH4502 Phase 1 nearing completion of dose escalation and cohort enrichment
- Sanofi deprioritized SAR514 (IPH6401) during Q1 2026
- At-the-Market program has $75M remaining balance available
- Prior 20-F filing (April 1, 2026) highlighted going concern risk and need for immediate financing
Financial Impact
Cash position of €25.4M with €20.3M in liabilities provides runway only to Q3 2026; revenue of €2.6M is insufficient to cover operating needs
Risk Factors
- Cash runway only until end of Q3 2026 — risk of dilutive equity raise or bankruptcy if financing not secured
- TELLOMAK-3 trial initiation dependent on non-dilutive financing — delay or failure would impair lacutamab's regulatory path
- Sanofi deprioritization of SAR514 reduces partnership optionality
- Going concern risk explicitly flagged in prior 20-F filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-034383 |
| Document: a2605136kincorporatediph.htm | 0001628280-26-034383 |
| Document: 0001628280-26-034383-index-headers.html | 0001628280-26-034383 |
| Document: 0001628280-26-034383-index.html | 0001628280-26-034383 |
| Document: 0001628280-26-034383.txt | 0001628280-26-034383 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 22w ago | 6-K | $2.25 $1.65 | ▼ −26.67% | ▼ −32.96% | $1.51 (−32.93%) |
May 13, 2026 23w ago | 6-K | $1.50 $1.65 | ▼ −10.00% | ▼ −5.56% | $1.51 (−0.60%) |
May 6, 2026 24w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +7.94% | $1.51 (+0.60%) |
Apr 23, 2026 26w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +4.98% | $1.51 (+0.60%) |
Apr 17, 2026 27w ago | 6-K | $1.50 $1.65 | ▲ +10.00% | ▲ +3.86% | $1.51 (+0.60%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 13, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +11.25% | $1.51 (+9.91%) |
Apr 8, 2026 28w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +9.72% | $1.51 (+9.91%) |
Apr 3, 2026 29w ago | 6-K | $1.37 $1.65 | ▲ +20.17% | ▲ +6.71% | $1.51 (+9.91%) |
Apr 1, 2026 29w ago | 20-F | $1.37 $1.65 | ▼ −20.17% | ▼ −6.80% | $1.51 (−9.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers